AR and posterior cortical atrophy: For the ARTAs or so called next-generation androgen receptor inhibitors such as enzalutamide, apalutamide and darolutamide, even better results are obtained in terms of a reduction in PCa progression in AS, but this is accompanied by very significant TRAEs, even in up to 88% of patients in the case of enzalutamide [24,26].